Title
Date
- Korean Biotech’s China Pivot: What the Rush to Chinese Clinical Trials Means for Sponsors Evaluating Korea
- The Obesity Drug Race Just Got Harder to Win: What CagriSema and Retatrutide Mean for Sponsors Evaluating Korea
- Decentralized Clinical Trials Are Going Mainstream: Is Korea Ready for the Shift?
- The First In Vivo CRISPR Therapy Just Cleared Phase 3: What Lonvo-z Means for Gene-Editing Trials in Korea
- Running Bispecific Antibody and T-Cell Engager Trials in Korea: A Sponsor’s Regulatory and Operational Playbook
- FDA and EMA’s 2026 AI and Bayesian Guidance: What the New Regulatory Convergence Means for Clinical Trial Design in Korea
- Is Your Combination Product Drug-Led or Device-Led in Korea? A Sponsor’s Guide to MFDS Classification and Dual-Track Review
- The First PROTAC Drug is Now FDA-Approved: What Vepdegestrant’s 2026 Breakthrough Means for the Next Wave of Targeted Protein Degradation Trials
- GLP-1 Drugs and Cancer: What ASCO 2026 Data Means for Oncology Clinical Trials in Korea
- What Global Biotechs Need Before Entering Korea in 2026